Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

Incidents Review Support and Records Management

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Food and Drug Administration’s Center for Drug Evaluation and Research (CDER), specifically the Office of Compounding Quality and Compliance (OCQC), is seeking contractor assistance to support the critical task of triaging incident reports related to compounded drug products. This support is essential for managing the high volume of adverse event reports, including those from the FDA’s Adverse Event Reporting System (FAERS) and MedWatch, as well as submissions from firms. The contractor’s responsibilities include recording, cataloging, and daily reviewing of incidents, as well as contacting reporters and firms to gather detailed information on whether the incidents relate to compounded drugs and the identities of the compounders involved. This contract addresses an urgent need for continued support due to an unprecedented increase in adverse event reports, which OCQC previously struggled to manage until contractor assistance was implemented in fiscal year 2024. The significance of this work is underscored by historical public health crises, such as the 2012 fungal meningitis outbreak linked to contaminated compounded drugs, which resulted in numerous deaths and infections nationwide. The ongoing monitoring and triaging of incident reports are critical to preventing similar large-scale adverse events and ensuring the safety and quality of compounded drug products. The contract is part of a forecast opportunity and falls under NAICS code 541611, involving record management and incident review activities.

General Info

Contractor supports FDA in triaging compounded drug incident reports to prevent public health risks.

Agency

Food and Drug Administration → Food And Drug Administration

NAICS

541611 - Administrative Management and General Management Consulting Services View NAICS

Place of Performance

US

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyFood and Drug Administration → Food And Drug Administration
Contacts2 people available
OfficeN/A
Organization / Agency
Food and Drug Administration → Food And Drug Administration
Office AddressN/A
Contacts
Cder Acquisition Liaison
To Be Determined To Be DeterminedContracting Officer

Full Description

Show more
The CDER's Office of Compounding Quality and Compliance (OCQC) is requesting contractor support with triaging incidents report information. There is also a critical need for support for incidents to help with daily triaging. We would like to continue current contractor support that is essential for recording and cataloging information that is reviewed by the point of contact on the incidents team daily. The contractor helps to triage and address the materials that come from FAERS, including MedWatch reports and reports submitted by firms. Contracted support staff assist with incident triaging by contacting reporters or firms who submit reports to FAERS to gather information about whether the incident was related to a compounded drug and the information about the compounder of that drug. There is an unprecedented volume of adverse event/incident reports. In the past, OCQC has struggled to keep up with triaging these reports until we were able to obtain contractor support beginning in FY24. Review of incidents is one way the OCQC helps to protect the public health from potentially serious adverse events that may be related to compounded drug products such as the 2012 fungal meningitis outbreak associated with contaminated compounded drugs shipped by the New England Compounding Center to patients and healthcare providers nationwide, causing over 60 deaths and 750 cases of infection. This incident was the most significant of a long history of serious adverse events resulting from compounded drug products. Both before and since this outbreak, FDA has investigated many serious adverse events and serious product quality issues, such as contamination or potency failures, associated with sterile and non-sterile compounded drug products. It is critical the OCQC maintain this additional support needed to keep up with the increased rate of adverse event reports to help prevent large scale serious adverse events.

Similar Contracts